Another vaccine strain utilizing measles virus engineered to express carcinoembryonic antigen (MV-CEA virus) was investigated in a Phase I study of patients with platinum resistance ovarian cancer who have normal CEA levels 87. The gene discussed is CEACAM5; the disease is ovarian cancer.